A Phase 1/2 Study of PRV-300 (JNJ-42915925/CNTO 3157) in patients with moderate to severe ulcerative colitis

Trial Profile

A Phase 1/2 Study of PRV-300 (JNJ-42915925/CNTO 3157) in patients with moderate to severe ulcerative colitis

Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs CNTO 3157 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 26 Sep 2017 New trial record
    • 21 Sep 2017 Provention expects to initiate this trial in the first half of 2018, as reported in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top